Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Bio-Rad Laboratories (BIO)

Tipranks - Tipranks - Sat Aug 2, 2025

Analysts have been eager to weigh in on the Healthcare sector with new ratings on AbbVie (ABBV – Research Report) and Bio-Rad Laboratories (BIO – Research Report).

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

AbbVie (ABBV)

Wells Fargo analyst Mohit Bansal maintained a Buy rating on AbbVie yesterday and set a price target of $240.00. The company’s shares closed last Thursday at $189.02.

According to TipRanks.com, Bansal is a 4-star analyst with an average return of 3.4% and a 52.4% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., Vertex Pharmaceuticals, and Jazz Pharmaceuticals. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AbbVie with a $214.08 average price target, implying an 8.6% upside from current levels. In a report issued on July 16, TR | OpenAI – 4o also upgraded the stock to Buy with a $206.00 price target.

See the top stocks recommended by analysts >>

Bio-Rad Laboratories (BIO)

Wells Fargo analyst Brandon Couillard maintained a Hold rating on Bio-Rad Laboratories today and set a price target of $265.00. The company’s shares closed last Thursday at $241.95, close to its 52-week low of $241.87.

According to TipRanks.com, Couillard is a 5-star analyst with an average return of 14.3% and a 59.7% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Myriad Genetics, and GeneDx Holdings. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bio-Rad Laboratories with a $320.67 average price target, a 29.7% upside from current levels. In a report issued on July 23, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $250.00 price target.

Read More on ABBV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).